AstraZeneca Pharma India names Atul Tandon CFO effective Nov 9

AstraZeneca Pharma India Limited has named Atul Tandon its full-time chief financial officer effective November 9, 2026, bringing an executive with around 26 years of industry experience who has led AstraZeneca Vietnam since December 2023. The filing says AstraZeneca Vietnam doubled revenue under his leadership.

When does Atul Tandon become AstraZeneca Pharma India CFO?

Atul Tandon becomes chief financial officer of AstraZeneca Pharma India on November 9, 2026, under a full-time employment arrangement. The November 5, 2026 filing describes the action as an appointment as CFO and does not identify a predecessor, a predecessor’s departure date or the reason for the change.

AstraZeneca Pharma India disclosed the CFO appointment in an annexure covering four leadership actions with effective dates from November 5 to December 1, 2026. Tandon’s start date of November 9 is shared by Nitin Bindal’s move to director of the Biopharmaceuticals Business Unit, while Kumaran Krishnan is due to become medical director of that unit on December 1.

The disclosure accompanied AstraZeneca Pharma India’s unaudited financial results for the quarter and half year ended September 30, 2026. The board approved those results on November 5, 2026, and B S R & Co. LLP issued an unmodified limited-review conclusion on the same date.

What experience does Atul Tandon bring to AstraZeneca Pharma India?

Tandon brings experience across finance, strategy, business development, diabetes, oncology and Asian biopharma operations from his AstraZeneca career since 2011. Before the India CFO role, he was responsible for the AstraZeneca Group’s Bio-Pharma Business for the Asia Area and was based in Singapore.

Since December 2023, Tandon has led AstraZeneca Vietnam Company Ltd. as chairman and general director. AstraZeneca Pharma India said that AstraZeneca Vietnam doubled revenue under his leadership, consistently outperformed its market by two to three times and reached the number-one position in every therapeutic area where it operated.

The filing does not provide revenue values, the specific comparison periods or a definition of the market measure behind the two-to-three-times statement. It does, however, distinguish Tandon’s Vietnam operating role from his earlier regional responsibility for the Asia Area biopharma business.

What is Atul Tandon’s background before this CFO role?

Tandon has around 26 years of diversified industry experience, including work with the Aditya Birla Group and ITC Ltd. AstraZeneca Pharma India said that, during his time at ITC, he was associated with E-Choupal, the company’s socio-economic initiative.

He also had a brief stint as vice president at Boston Analytics, a boutique research and advisory firm. According to the filing, he executed emerging-market strategy and organisation-redesign projects for globally known consumer packaged goods companies, although it does not disclose dates or duration for that role.

Tandon is a Chartered Accountant and holds a Master of Business Administration degree from the Indian School of Business, Hyderabad. Those qualifications accompany an AstraZeneca career that has included leadership of teams in finance, strategy, business development, diabetes and oncology since 2011.

What other leadership changes did AstraZeneca Pharma India disclose?

AstraZeneca Pharma India disclosed four leadership changes, including Tandon’s appointment, between November 5 and December 1, 2026. The other three actions cover independent board oversight, the Biopharmaceuticals Business Unit and medical leadership.

Krishnamurthy Narayanan Iyer was appointed an additional director, non-executive and independent, from November 5, 2026 for a five-year term. AstraZeneca Pharma India said Iyer has more than four decades of leadership experience and was managing director, president and chief executive officer of Walmart India from 2014 to 2020.

Nitin Bindal becomes director of the Biopharmaceuticals Business Unit from November 9 under full-time employment. The filing says Bindal has more than 17 years of pharmaceutical-industry experience and, at Bristol Myers Squibb, led access and market penetration for immunotherapies across 20 indications as Business Unit Director for Oncology and Haematology.

Kumaran Krishnan will become medical director of the Biopharmaceuticals Business Unit from December 1 under full-time employment. AstraZeneca Pharma India said Krishnan joined AstraZeneca in 2021 and has delivered more than 20 new product launches during a pharmaceutical career spanning more than three decades.

What financial and regulatory issues were disclosed with the appointment?

AstraZeneca Pharma India reports healthcare as its only reportable segment under Indian Accounting Standard 108, Operating Segments. It therefore did not provide financial information by therapy area, geography or individual product in the supplied September 30, 2026 results.

The company received an order from the National Pharmaceutical Pricing Authority seeking Rs 14.87 crore, including interest, over alleged overcharging of a combination respiratory drug sold from May 2016 to November 2025. A reminder notice dated October 5, 2026 sought Rs 15.12 crore, including interest calculated to October 30, 2026.

AstraZeneca Pharma India said the High Court directed on October 29, 2026 that no coercive collection action be taken until the next hearing, listed for January 11, 2027. Management said, based on its assessment and external legal advice, it had reasonable grounds to defend its position, and the company made no provision in the financial statements.

Separately, operations at the Bangalore manufacturing site ceased during the quarter ended June 30, 2025 and AstraZeneca Pharma India is processing the sale of related assets. Closure-related exceptional items were a cost of Rs 6.5 lakh for the quarter ended September 30, 2026, compared with a reversal of Rs 52.9 lakh in the quarter ended September 30, 2025.

Conclusion

AstraZeneca Pharma India’s November 9, 2026 CFO appointment brings Tandon from an AstraZeneca career spanning finance, strategy, business development, therapeutic business teams and leadership of the Vietnam company. His arrival is one of four disclosed changes, combining finance leadership with a new independent director and new biopharma business and medical roles.

Investors can watch the November 9 effective date for Tandon and Bindal, followed by Krishnan’s planned December 1 start. The next stated external event is the January 11, 2027 High Court hearing on the National Pharmaceutical Pricing Authority demand, while the Bangalore-site asset-sale process has no disclosed completion date.